At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 34 enrolled
Drug / intervention
abataceptbiological
Likely dose
abatacept 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Structural Benefits of Injectable Abatacept as Measured by MRI in RA Patients Who Have Failed Prior Anti-Tumor Necrosis (TNF) Therapy and Correlated With Clinical Outcomes
Arthritis & Rheumatic Disease Specialties Research·interventional·Posted May 11, 2011·Updated Mar 13, 2017
In Brief
A Phase 3 clinical trial evaluating abatacept for Rheumatoid Arthritis. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if the use of sub-cutaneous (SC) abatacept provides any structural benefit in patients with rheumatoid arthritis who have failed prior use of TNF therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJun 2011
Primary CompletionJan 2014
Study CompletionApr 2014
TodayJul 2026
First PostedMay 11, 2011
Enrollment StartJun 1, 2011
Primary CompletionJan 1, 2014
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.1 years ago
Interventions
abataceptbiological
Abatacept administered SC weekly at 125 mg dose